263 related articles for article (PubMed ID: 24252799)
1. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
Suzuki S; Shibata K; Kikkawa F; Nakatsura T
Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
[TBL] [Abstract][Full Text] [Related]
2. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
3. [Cancer peptide vaccine targeted glypican-3 antigen].
Nakatsura T
Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
[TBL] [Abstract][Full Text] [Related]
5. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract][Full Text] [Related]
6. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
[TBL] [Abstract][Full Text] [Related]
7. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
Nishimura Y; Nakatsura T; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccines for hepatocellular carcinoma.
Nobuoka D; Yoshikawa T; Sawada Y; Fujiwara T; Nakatsura T
Hum Vaccin Immunother; 2013 Jan; 9(1):210-2. PubMed ID: 23442593
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.
Suzuki S; Sakata J; Utsumi F; Sekiya R; Kajiyama H; Shibata K; Kikkawa F; Nakatsura T
Oncoimmunology; 2016; 5(11):e1238542. PubMed ID: 27999758
[TBL] [Abstract][Full Text] [Related]
11. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
[TBL] [Abstract][Full Text] [Related]
12. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
13. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case.
Sawada Y; Yoshikawa T; Fujii S; Mitsunaga S; Nobuoka D; Mizuno S; Takahashi M; Yamauchi C; Endo I; Nakatsura T
Hum Vaccin Immunother; 2013 Jun; 9(6):1228-33. PubMed ID: 23466818
[TBL] [Abstract][Full Text] [Related]
14. [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma].
Komori H; Nakatsura T; Beppu T; Nishimura Y; Baba H
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1742-4. PubMed ID: 17212093
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
[TBL] [Abstract][Full Text] [Related]
16. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.
Tada Y; Yoshikawa T; Shimomura M; Sawada Y; Sakai M; Shirakawa H; Nobuoka D; Nakatsura T
Int J Oncol; 2013 Oct; 43(4):1019-26. PubMed ID: 23903757
[TBL] [Abstract][Full Text] [Related]
17. Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma.
Ikeda M; Okusaka T; Ohno I; Mitsunaga S; Kondo S; Ueno H; Morizane C; Gemmoto K; Suna H; Ushida Y; Furuse J
Immunotherapy; 2021 Apr; 13(5):371-385. PubMed ID: 33525928
[No Abstract] [Full Text] [Related]
18. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
20. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]